Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial

AIMS: Hypoglycaemia, in patients with Type 2 diabetes (T2D) is associated with an increased risk for cardiovascular (CV) events. In EMPA-REG OUTCOME, the sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the risk of CV death by 38% and heart failure hospitalization (HHF) by 35%, while...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitchett, David, Inzucchi, Silvio E, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Vedin, Ola, Zinman, Bernard, Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945517/
https://www.ncbi.nlm.nih.gov/pubmed/31504427
http://dx.doi.org/10.1093/eurheartj/ehz621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945517/
https://www.ncbi.nlm.nih.gov/pubmed/31504427
http://dx.doi.org/10.1093/eurheartj/ehz621

Ejemplares similares